Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology
company developing placental-derived off-the-shelf allogeneic cell
therapies and advanced biomaterial products, today announced the
appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of
Directors. Dr. Ling, a distinguished academic and military
physician-scientist with a strong background in regenerative
medicine and a deep commitment to advancing healthcare, will bring
invaluable expertise and insights to Celularity as it continues to
pioneer innovative therapies for patients in need.
Throughout his career, Dr. Ling has made
significant contributions to regenerative medicine and stem cell
therapy, earning him recognition as a thought leader in these
areas. He has published numerous research papers on innovative
cellular therapies. His profound understanding of the intricate
biological processes underpinning cell-based treatments makes him
an ideal addition to Celularity's Board of Directors. Leveraging
Dr. Ling’s outside perspective and deep expertise in stem cell
therapy, Celularity hopes to unlock the full potential of
placental-derived cells and tissues.
“We are honored to welcome Geoff to the
Celularity Board of Directors,” said Robert J. Hariri, M.D., Ph.D.,
founder, Chairman and Chief Executive Officer of Celularity. “We
believe Geoff’s decades-long success record in academia, the
military, government and the biopharmaceutical industry will serve
Celularity well as we look to progress our pipeline of
investigational products to deliver ‘off-the-shelf’ cellular and
regenerative therapies faster, more reliably, and at greater scale
to more patients. I have long admired Geoff’s career and
contributions to medicine and biotechnology, his service to our
nation, and have been privileged to share some common background in
our careers.”
Dr. Ling commented on his new role, "I am
thrilled to join the board of Celularity, a company known for its
groundbreaking work in cellular therapies. I look forward to
collaborating with my fellow board members and the talented team at
Celularity to further advance the development of transformative
treatments that have the potential to change lives."
Dr. Ling brings more than 30 years of experience
in pharmaceutical, governmental, and academic organizations to his
new role. Most recently, he co-founded On Demand Pharmaceuticals –
developing advanced, miniaturized, and automated pharmaceutical
manufacturing systems that create from precursors to final
formulated drugs. He also serves as a Professor of Neurology and an
Attending Neurocritical Care physician at Johns Hopkins University
and Hospital and the Uniformed Services University of the Health
Science (USUHS). Dr. Ling previously served as the Founding
Director of the Biological Technologies Office at the Defense
Advanced Research Projects Agency (DARPA) and as Assistant Director
for Medical Innovation of the Science Division in President Obama’s
White House Office of Science and Technology Policy (OSTP). He
is a retired U.S. Army colonel who served for 27 years and was
deployed to Iraq and Afghanistan.
Dr. Ling obtained his medical degree from
Georgetown University and his doctorate in Pharmacology is from
Cornell University. He was a postdoctoral research fellow at
Memorial Sloan Kettering Cancer Center, completed his neurology
residency at Walter Reed Army Medical Center, and his Neuro
Critical Care fellowship at Johns Hopkins. Dr. Ling has published
over two hundred peer-reviewed articles, book chapters and
reviews. He is a member of the honor societies of Alpha Omega
Alpha, Sigma Xi, and the Military Medical Order of Merit. He is a
fellow of the American Neurological Association, American Academy
of Neurology and Neurocritical Care Society. Dr. Ling is a member
of the Society for Critical Care Medicine, the American Society of
Pharmacology and Experimental Therapeutics, and AMSUS (the
Association of Military Surgeons of the United States).
Celularity also announced today that Andrew von
Eschenbach, M.D., will step down from his position on the Board of
Directors. “I want to thank Andy for his service as a director
since Celularity’s formation and for his advice and guidance during
this important period of the company,” said Hariri. “Celularity
would not exist had I not had the support and counsel of Dr. von
Eschenbach and for that I am deeply grateful. We have made
significant clinical and therapeutic advancements in the last six
years and are indebted for the role he helped to play in
positioning Celularity for continued success.”
About Celularity
Celularity Inc. (Nasdaq: CELU) headquartered in
Florham Park, N.J., is a biotechnology company leading the next
evolution in cellular and regenerative medicine by developing
allogeneic cryopreserved off-the-shelf placental-derived cell
therapies, including therapeutic programs using mesenchymal-like
adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR
T-cells), and genetically modified and unmodified natural killer
(NK) cells. These therapeutic programs target indications in
autoimmune, infectious and degenerative diseases, and cancer. In
addition, Celularity develops, manufactures and commercializes
innovative biomaterial products also derived from the postpartum
placenta. Celularity believes that by harnessing the placenta’s
unique biology and ready availability, it can develop therapeutic
solutions that address significant unmet global needs for
effective, accessible, and affordable therapies.
Forward-Looking Statements
This press release includes “forward-looking
statements” within the meaning of The Private Securities Litigation
Reform Act of 1995, as well as within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. All statements other
than statements of historical facts are “forward-looking
statements,” including those relating to future events. In some
cases, you can identify forward-looking statements by terminology
such as “anticipate,” “believe,” “can,” “contemplate,” “continue,”
“could,” “estimate,” “expect,” “forecast,” “intends,” “may,”
“might,” “outlook,” “plan,” “possible,” “potential,” “predict,”
“project,” “seek,” “should,” “strive,” “target,” “will,” “would”
and the negative of terms like these or other comparable
terminology, and other words or terms of similar meaning. The
forward-looking statements in this press release include statements
regarding Celularity’s ability to progress its pipeline of
investigational products to deliver ‘off-the-shelf’ cellular and
regenerative therapies faster, more reliably, and at greater scale
to more patients, among others. Many factors could cause actual
results to differ materially from those described in these
forward-looking statements, including the inherent risks in
biotechnological development, the risks associated with
Celularity’s current liquidity, developments relating to the
biotechnology industry, along with those risk factors set forth
under the caption “Risk Factors” in Celularity’s annual report on
Form 10-K filed with the Securities and Exchange Commission (SEC)
on March 31, 2023, and other filings with the SEC. These risks and
uncertainties may be amplified by current economic situations,
including inflation, supply chain issues and overall economic
uncertainty. If any of these risks materialize or underlying
assumptions prove incorrect, actual results could differ materially
from the results implied by these forward-looking statements. There
may be additional risks that Celularity does not presently know, or
that Celularity currently believes are immaterial, that could also
cause actual results to differ from those contained in the
forward-looking statements. In addition, these forward-looking
statements reflect Celularity’s current expectations, plans, or
forecasts of future events and views as of the date of this
communication. Subsequent events and developments could cause
assessments to change. Accordingly, forward-looking statements
should not be relied upon as representing Celularity’s views as of
any subsequent date, and Celularity undertakes no obligation to
update forward-looking statements to reflect events or
circumstances after the date hereof, whether as a result of new
information, future events or otherwise, except as may be required
under applicable securities laws.
To learn more, visit celularity.com
Celularity Media/Investor Contact:
Carlos Ramirez, SVP Investor
RelationsCelularitycarlos.ramirez@celularity.com
Factory PRcelularity@factorypr.com
Celularity (NASDAQ:CELU)
Historical Stock Chart
From Apr 2024 to May 2024
Celularity (NASDAQ:CELU)
Historical Stock Chart
From May 2023 to May 2024